The aspartate aminotransferase to platelet ratio before chemotherapy predicts adverse events for FOLFOX and XELOX regimens including bevacizumab as the first-line therapy for stage IV, recurrent and metastatic colorectal cancer

BACKGROUND: Oxaliplatin-based chemotherapy for colorectal liver metastasis can induce hepatotoxicity, which increases the risk of liver resection. We previously reported that the aspartate aminotransferase to platelet ratio (APR) before chemotherapy can indicate oxaliplatin-induced splenomegaly and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sato, Sumito, Nakano, Hiroshi, Ishida, Yasuo, Otsubo, Takehito
Formato: Artigo
Idioma:Inglês
Publicado em: Pioneer Bioscience Publishing Company 2013
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3635181/
https://ncbi.nlm.nih.gov/pubmed/23730517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2013.016
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados